Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

PLoS medicine - 1 Nov 2005

Greulich Heidi, Chen Tzu-Hsiu, Feng Whei, Jänne Pasi A, Alvarez James V, Zappaterra Mauro, Bulmer Sara E, Frank David A, Hahn William C, Sellers William R, Meyerson Matthew

Abstract excerpt

BACKGROUND: Somatic mutations in the kinase domain of the epidermal growth factor receptor tyrosine kinase gene EGFR are common in lung adenocarcinoma. The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations and their relationship to drug sensitivity have not been described. METHODS AND FINDINGS: Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Mice, Nude

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 16187797
DOI: 10.1371/journal.pmed.0020313
PMCID: PMC1240052

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.PMID 16187797Read ↗

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.Semantic proximity Read ↗

Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo.Semantic proximity Read ↗

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.Semantic proximity Read ↗

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.Semantic proximity Read ↗

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to ErlotinibSemantic proximity Read ↗

A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer.Semantic proximity Read ↗

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.Semantic proximity Read ↗

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.Semantic proximity Read ↗

The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1Semantic proximity Read ↗

Ligand-Independent EGFR Signaling.Semantic proximity Read ↗

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.